Swiss-based biopharmaceutical company Inthera Bioscience has completed a series A financing round led by Merck Ventures to raise Sfr10.5m ($10.53m).
Aglaia BioMedical Ventures, Novo Seeds and other private investors also participated in the round.
Go deeper with GlobalData
US-based biotechnology company Sea Lane Biotechnologies has sold its entire antibody and engineered protein technology portfolio to i2 Pharmaceuticals, a biopharmaceutical company also based in the US.
The portfolio includes human antibody libraries, human b-cell derived antibodies and surrobodies, which enable facile creation of bispecific therapeutic agents from arrays of monospecific agents.
Chinese biotechnology company InventisBio has completed a series B venture financing round to raise $19m.
See Also:
The proceeds will be used to advance the company’s product development through phase one clinical trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataRigel Pharmaceuticals intends to raise $40m in gross proceeds through a public offering of shares of its common stock.
The US-based pharmaceutical company intends to use the proceeds for general corporate purposes.
